Navigation Links
Nuvilex Introduces Last Shot Hangover Remedy(TM) Video
Date:8/27/2009

CHERRY HILL, N.J., Aug. 27 /PRNewswire-FirstCall/ -- Nuvilex, Inc. (OTC Bulletin Board: NVLX), today announces that its Last Shot Hangover Remedy(TM) ("Last Shot") video commercial will begin airing on Monday, August 31, 2009. The video is a part of the Company's emerging Last Shot brand awareness campaign that will ultimately include television, radio, Internet, cinema spots, billboard, print and point-of-sale advertising. The video will initially be introduced to the public through the Internet. The video is adaptable for long and short segment play. The Last Shot video can be previewed from the Nuvilex (www.nuvilex.com) and Last Shot (www.mylastshot.com) web sites starting Friday, August 28, 2009.

About Nuvilex, Inc.

Nuvilex, Inc. is an emerging healthcare consumer products company. The Company's lead products include: Last Shot Hangover Remedy, a unique sugar-free, calorie-free and caffeine-free liquid formula designed to ease the symptoms of a hangover; Cinnergen, which promotes a healthy glucose metabolism; Cinnechol, designed to help maintain normal cholesterol levels and support normal cardiovascular function; and Infinitink( (R)), a permanent yet more easily removable tattoo ink. The Company's complete portfolio spans aesthetics, skin care, environmental and nutraceutical products, all of which are designed to directly or indirectly improve human health. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., the developer of Infinitink( (R)). In conjunction with the merger, the Company changed its name to Nuvilex, Inc. from eFoodSafety.com. Please visit www.nuvilex.com for additional information on the Company.

Safe Harbor Statement

Statements contained in this presentation that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Forward-looking statements are sometimes identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and involve a number of risks and uncertainties that could cause the Company's actual results to differ materially from projected results. All parties are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, the planned share exchange with Freedom2 Holdings, Inc., our ability to secure additional financing, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.

    Company Contact:

    Blair Barnes
    Senior Vice President and Chief Financial Officer
    Nuvilex, Inc.
    Ph: 856-433-6088
    Email: bbarnes@nuvilex.com

    Press Contact:

    Pat Arcand
    Arcand & Madison
    Ph: 617-576-7777
    Email: pat@am-pr.com


'/>"/>
SOURCE Nuvilex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nuvilex Launches Last Shot Hangover Remedy(TM) Web Site
2. Nuvilex to Issue Positive Shareholder Newsletter
3. Nuvilex Completes First Sale of Last Shot Hangover Remedy(TM)
4. Nuvilex, Inc. Announces Business Update Conference Call
5. Nuvilex Cites Study that Suggests Red Yeast Rice, an Active Ingredient in Cinnechol, Can Help to Improve Cardiovascular Health
6. Nuvilex Renews MedX Master Distribution Agreement and Implements New Pricing for Talsyn Scar Cream
7. Nuvilex Featured in Wall Street Reporter Interview
8. Nuvilex Offers Free Cinnergen Samples in Response to Spike in Consumer Interest
9. Nuvilex Launches Video Marketing Campaign
10. Nuvilex Gets Update from CK41 on purEffect(TM) Launch Plan
11. Nuvilex Signs Agreement with Jayhur Enterprises to Distribute Infinitink - the Worlds First Permanent, But Easier to Remove Tattoo Ink - in Australia and New Zealand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... The president released a ... Health System but would shift more of the cost burden to military beneficiaries. ... laid out in the defense budget as including limited quantifiable benefit fixes mixed with ...
(Date:2/11/2016)... ... February 11, 2016 , ... In a new paper ... surgeon , Dr. Rod J. Rohrich, and colleagues, examine and underscore the importance ... for rhinoplasty surgeons when addressing this vital area. , The upper lateral cartilage ...
(Date:2/11/2016)... ... 11, 2016 , ... PharmMD CEO Robert Yeager ... focus on contract negotiations, corporate strategy and healthcare data law. Additional responsibilities will ... in data breaches for the Part D Star Rating improvement and Medication Therapy ...
(Date:2/11/2016)... ... February 11, 2016 , ... Talix ... Family Practice , will be presenting at the 2016 HIMSS Annual Conference & ... , During his session, “ Coding for Care: Using Data Analytics for ...
(Date:2/11/2016)... ... 2016 , ... Be Well Medical Group (Be Well) is pleased ... at 108 South Columbus St, Suite 201, Alexandria, VA. Be Well Medical Group is ... the convenience of their homes, offices or at the practices’ local office. It is ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... has taken Kickstarter by storm, crowdfunding over $60,000 – or 120% of its original funding goal. With ... to backers starting May of this year. Photo - ... ... ... Created by NAMU, a team of biomedical engineers out of South Korea ...
(Date:2/11/2016)... 11, 2016 Transformational M&A achieved through ...   --> Transformational M&A achieved through NPS and ... --> Transformational M&A achieved through NPS and Dyax ... Positioned for future growth with most robust pipeline in Shire ... for future growth with most robust pipeline in Shire ...
(Date:2/11/2016)... Feb. 11, 2016 Brain Cancer patients ... method at West Cancer Center . Optune™, ... to inhibit cancer cell replication causing death of cancer ... a decade to show a significant extension in overall ... patients. Currently, West Cancer Center is the only medical ...
Breaking Medicine Technology: